Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies

Expectations that the US central bank would soon reverse its monetary policy stance proved to be premature. The rise in bond yields weighed heavily on biotech stocks as well as the stock market in general. At the same time biotech investors were closely following recent action by US agencies such as the Federal Trade Commission (FTC), which softened its stance of challenging proposed takeover transactions.